TP-3654
- Generic Name
- TP-3654
- Brand Names
- Relyvrio
- Drug Type
- Small Molecule
- Chemical Formula
- C22H25F3N4O
- CAS Number
- 1361951-15-6
- Unique Ingredient Identifier
- EOB0N7BOY4
- Background
Tauroursodeoxycholic acid, also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid that is produced in humans at a low concentration. It is a taurine conjugate of ursodeoxycholic acid with comparable therapeutic efficacy and safety, but a much higher hydrophilicity. Normally, hydrophilic bile acids regulates hydrophobic bile acids and ...
- Indication
Tauroursodeoxycholic acid is used to prevent and treat gallstone formation.
Tauroursodeoxycholic acid is used in combination with phenylbutyric acid to treat amyotrophic lateral sclerosis (ALS) in adults.
- Associated Conditions
- Amyotrophic Lateral Sclerosis (ALS), Gallstones
- Associated Therapies
- -
Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis
- Conditions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 39
- Registration Number
- NCT00004441
- Locations
- 🇺🇸
Children's Hospital of Denver, Denver, Colorado, United States
🇺🇸Children's Hospital Medical Center - Cincinnati, Cincinnati, Ohio, United States
🇮🇹University of Milan, Milan, Italy
Randomized Study of Tauroursodeoxycholic Acid in Prophylactic Therapy of Total Parenteral Nutrition Associated Cholestasis in Infants
- Conditions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 50
- Registration Number
- NCT00004410
- Locations
- 🇺🇸
Children's Hospitals and Clinics - Minneapolis, Minneapolis, Minnesota, United States
🇺🇸Children's Hospital Medical Center - Cincinnati, Cincinnati, Ohio, United States
🇺🇸University of Mississippi Medical Center, Jackson, Mississippi, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.